Piper Sandler raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $87 from $77 and keeps an Overweight rating on the shares. Following a number of Q4/FY25 pre-releases in recent weeks and ahead of Q4 reporting, the firm is taking the opportunity to review and adjust its estimates for some of its commercial names, as well as some price targets.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals assumed with an Overweight at Barclays
- Ionis Pharmaceuticals announces European Commission approval for Dawnzera
- Cathie Wood Doubles Down on High-Potential Biotech Plays
- RBLX, META, GH, IONS: Cathie Wood Loads Up on Roblox, Trims Meta and Biotech Stocks
- Ionis Pharmaceuticals: Underappreciated Bepirovirsen and Multiple Late-Stage Catalysts Support Buy Rating